Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,485 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension period.
Warren RB, Lebwohl M, Thaçi D, Gooderham M, Pinter A, Paul C, Gisondi P, Szilagyi B, White K, Deherder D, Staelens F, Lambert J, Strober B. Warren RB, et al. Br J Dermatol. 2025 Jan 25:ljaf032. doi: 10.1093/bjd/ljaf032. Online ahead of print. Br J Dermatol. 2025. PMID: 39862230
Orismilast, a PDE4B/D inhibitor, in moderate-to-severe atopic dermatitis: Efficacy and safety from a multicenter, randomized, placebo-controlled, phase 2b dose-ranging study (ADESOS).
Silverberg JI, Eichenfield LF, Blauvelt A, Irvine AD, Guttman-Yassky E, Langley RG, Warren RB, French LE, Felding J, Weiss A, Pedersen CB, Jensen ML, Carlsson A, Sommer MOA, Kjøller K, Simpson EL. Silverberg JI, et al. Among authors: warren rb. Br J Dermatol. 2025 Jan 7:ljae507. doi: 10.1093/bjd/ljae507. Online ahead of print. Br J Dermatol. 2025. PMID: 39847538
Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.
Warren RB, Pavlovsky L, Costanzo A, Bukhalo M, Korman NJ, Huang YH, Kokolakis G, Pinter A, Ibrahim N, Zheng Y, Drogaris L, Stakias V, Soliman AM, Rubant S, Thaçi D. Warren RB, et al. Dermatol Ther (Heidelb). 2025 Jan 17. doi: 10.1007/s13555-024-01328-4. Online ahead of print. Dermatol Ther (Heidelb). 2025. PMID: 39821856 No abstract available.
Latissimus Dorsi Tendon Transfer and Reverse Shoulder Arthroplasty: Restoring Mechanical Advantage by Transfer Posterior to the Long Head of the Triceps Tendon.
Bobko A, Uppstrom TJ, Jahandar A, Cecere R, Nicholson AD, Kontaxis A, Gulotta LV, Dines DM, Warren RF, Fu MC, Taylor SA, Blaine TA. Bobko A, et al. Among authors: warren rf. J Shoulder Elbow Surg. 2024 Dec 23:S1058-2746(24)00938-8. doi: 10.1016/j.jse.2024.10.020. Online ahead of print. J Shoulder Elbow Surg. 2024. PMID: 39722338
3,485 results